IBIrla Carla de França Barbosa

Irla Carla de França Barbosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irla Carla de França Barbosa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Segunda fase dos medicamentos genéricos no Brasil: implementação do estudo Vasoconstritor para corticoides tópicos dermatológicos

    by Leila Bastos Leal, Irla Carla de França Barbosa, Cristiano Ferraz, Davi Pereira de Santana

    Introduction: In Brazil, the sale of generic medicines has been increasing, driven by the search for more affordable alternatives. However, this expansion necessitates the assurance of safety and efficacy, particularly in the case of topical medications containing corticosteroids. Until 2022, these products were exempt from bioequivalence testing, with only pharmaceutical equivalence being required. Objective: This study aimed to discuss the registration of topical medications containing corticosteroids in Brazil, highlighting recent regulatory changes and the impact of the mandatory implementation of the Vasoconstrictor Assay (VCA). Method: The methodology consisted of a systematic review of scientific literature and national and international regulatory guidelines, focusing on the registration criteria for topical corticosteroid medications. The study provided a detailed examination of the VCA, a pharmacodynamic test that evaluates the degree of skin blanching following drug application, divided into a pilot study (defining Emax and ED50) and a main study (comparison with the reference product). Results: It was demonstrated that the VCA is widely adopted in international regulatory contexts, such as by the U.S. Food and Drug Administration (FDA) since 1995. In Brazil, its introduction presents a technical challenge, as most bioequivalence centers require appropriate expertise and infrastructure. Nevertheless, studies indicate that the method has the potential to effectively demonstrate bioequivalence. Conclusions: The requirement of the VCA represents a regulatory milestone in Brazil, fostering greater technical rigor in the registration of topical corticosteroid medications. Its adoption is essential to ensure the quality, safety, and efficacy of these products for the population.

  • Open Access

    Association of Rhizophora mangle and ascorbic acid in hydrogels: Evaluation of cytotoxic and immunomodulatory effects

    by Eduarda Santos de Santana, Leila Bastos Leal, Luzia Abílio da Silva, Irla Carla de França Barbosa, Cristiane Moutinho Lagos de Melo, Dayane Kelly Dias Do Nascimento Santos, Jeymesson Raphael Cardoso Vieira

    Polyphenolics from Rhizophora mangle (R. mangle) have shown wound healing and anti- inflammatory effects that may be potentiated by being associated with ascorbic acid, an important substance for collagen and elastin synthesis that plays a role in tissue repair. In our study, we aimed to formulate an association of R. mangle and ascorbic acid in hydrogels and evaluate the association’s cytotoxic and immunomodulatory effects. In a pre-formulation study, three gelling polymers (i.e.xanthan gum, poloxamer and hydroxyethyl cellulose) were tested. The selected polymer (i.e. xanthan gum) was used to evaluate cytotoxic and immunomodulatory effects using flow cytometry. Xanthan gum (1.5%) had a homogeneous appearance, an orange colour, a smooth surface, intense brightness and the typical odour, as well as non-Newtonian pseudoplastic behaviour. With a pH of 5.0-5.3 and a non-cytotoxic profile, xanthan gum induced the proliferation and activation of CD4 +, CD8+ and NK T lymphocytes and the production of IL- 2, IL-4, IL-10, IL-17 and TNF-α cytokines in stimulated splenocytes. The results suggest that the association of R. mangle and ascorbic acid in 1.5% xanthan gum hydrogel may be promising in preparations for wound-healing processes.


  • Prevention of necrosis in ischemic skin flaps using hydrogel of Rhizophora mangle

    by Luzia Abilio da Silva, Eduardo Carvalho Lira, Leila Bastos Leal, Eduarda Santos de Santana, Irla Carla de França Barbosa, Yuri José de Albuquerque Silva, Severino Alves Junior, Jeymesson Raphael Cardoso Vieira


  • Open Access

    Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review

    by Stephanye Carolyne Christino Chagas, Francisca Sueli Monte Moreira, Irla Carla França Barbosa, Osvaldo de Sousa Leal Júnior, Leila Bastos Leal, Davi Pereira de Santana

    BACKGROUND: The World Health Organization has declared that a pandemic situation exists in relation to the disease caused by the new coronavirus, COVID-19. So far, the absence of a vaccine against the new coronavirus has led people worldwide to seek various therapeutic alternatives, including use of cholecalciferol. DESIGN AND SETTING: Narrative review developed by a research group at a public university in Recife (PE), Brazil. METHODS: We searched the literature on the use of cholecalciferol for prevention or treatment of COVID-19, using the MEDLINE and LILACS databases, with the keywords “vitamin D”, “cholecalciferol”, “SARS-CoV-2”, “COVID-19” and “coronavirus”, from January 1, 2020, to June 10, 2020. Narrative reviews, cohort studies and ecological studies were selected. RESULTS: We retrieved 32 references, of which 8 were considered eligible for intensive review and critical analysis. These comprised five narrative reviews, two observational studies and one protocol proposal. Most of the studies selected reported positive effects from use of vitamin D for prevention or treatment of COVID-19. However, there was little quantitative data to assess the real impact of using this vitamin as an intervention against this disease. CONCLUSIONS: Current studies on vitamin D used for purposes other than bone health promotion cannot be taken as support to justify its use in a disease as recent as COVID-19. Studies of greater robustness, with higher levels of clinical evidence, need to be conducted. Rational use of this vitamin needs to be ensured, thereby minimizing the impacts on the patient and the public healthcare system.